Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
32 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-12-01
Study Completion Date
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to use gold particles as a model compound to modulate specifically and selectively the function of macrophages and mast cells and investigate how this modulates pain and pain sensitization in the osteoarthritic knee assessed by mechanistic pain assessment technologies
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intraarticular Gold Microparticles for Knee Osteoarthritis
NCT07202390
Knee Osteoarthritis
NOT_YET_RECRUITING
NA
Gold Against Pains From Osteoarthrosis in the Knee
NCT00378339
Arthritis
WITHDRAWN
PHASE2
Feasibility Study of Anti-inflammatory Cytokines in Whole Blood in Osteoarthritis Patients
NCT01050894
Osteoarthritis
COMPLETED
Intraarticular Gold Microparticles for Hip Osteoarthritis
NCT06186115
Osteoarthritis, Hip
NOT_YET_RECRUITING
Effect of Anti-inflammatory (ITIS) Diet in Knee Osteoarthritis
NCT05559463
Osteoarthritis, Knee
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Osteoarthritis (OA) of the knee and hip is the most common musculoskeletal joint disease worldwide. Although a major symptom of OA is chronic joint pain, which has a significant effect on patients' quality of life, the pain mechanisms remain largely unknown.
Recently, clinical studies have suggested the existence of a neuropathic component in OA pain \[5\]. Accumulating evidence has been indicating that painful OA patients show peripheral and central sensitization \[3,16\]. Quantitative sensory testing (QST) is a relevant way to assess peripheral and central sensitization in joint pain \[9\]. The majority of studies have administered mechanical stimuli, and the most commonly used modality have been pressure. A recent review concluded that that people with OA have lower Pressure Pain Thresholds (PPT), facilitated temporal summation and impaired conditioned (CPM) compared with healthy controls \[5\]. Also, recent evidence have link QST profiles to the development of chronic pain \[29,38\], which emphasises the importance of studying the central nervous system.
Inflammation markers have been correlated with the pain intensity \[35\], and systemic inflammation can leads to sensitization of peripheral nociceptors \[1\]. Recently it was reported that higher preoperative levels of TNF-α, MMP-13 and IL-6 in synovial fluid may indicate a smaller improvement in pain 2 years after TKR \[15\].
Injectable solutions of gold-thio-compounds have been used to treat rheumatoid arthritis for nearly 100 years \[13,21\]. Several studies suggest that gold ions reduces pain, joint swelling, inflammation, and increase joint motility \[24,31,33\]. Gold salt therapy (auranofin; RidauraR) has been vetted by the FDA and approved (May 1985) and recommended by the American College of Rheumatology as a Disease Modifying Anti Rheumatic Drug - DMARD (https://www.rheumatology.org).
Gold salts, whether injected or given orally, have been shown to be effective \[33,37\] in reducing joint pain. Studies report patients going to total remission \[28\] and others report a 30% reduction in symptoms \[20,27\]. In addition, Clark et al., 1997 \[8\] concluded in a Cochrane meta-analysis that systemic treatment with gold was highly effective compared to placebo.
The use of gold salt given systemically have been criticized, since when gold compounds are made to circulate systemically via the circulatory system after oral or parenteral administration, the gold ions reach essentially all tissues and organs. In some patients, organs that are not involved in the arthritic disease, such as the kidneys, liver, and skin are adversely affected by gold. About 30% of patients develop such remote-organ "side effects" and discontinue gold treatment \[20\]. In addition, newer drugs have been developed with efficacy almost equal to gold ions in many patients, and less toxic.
To overcome the toxicity, a method that captures the efficacy of the gold ions but eliminates the remote side effects have been developed\[10,23\]. Briefly, the method isolates the gold ions within the affected joints by injecting solid gold metal directly into the diseased joint, whereby a very slow dissolution and local diffusion deliver the therapeutic gold ions to affected areas within the joint. In this therapy, 99.99% pure gold implants are injected into the body.
Individual single beads are implanted with a 15-16 gauge needle based on an X-ray picture in deeply anesthetized animals close to the capsule of the affected joint(s) (videos www.goldtreat.com). Over 3000 dogs, and more than 100 horses have had this treatment for osteoarthritis at 50+ veterinary clinics and hospitals throughout Europe. (www.goldtreat.com ). Success rates of 50 - 70% are quoted (www.goldtreat.com), and a double-blind, placebo controlled study on dogs showed improvement in over 80% of the dogs, which continues for 18 months \[18\] as the gold particles remain in the joint\[26\].
The systemic concentration of released gold ions is low but clinically effective and because the gold ions do not spread in the organism, but instead stay local, the technique is safe \[12\]. The trials to date indicate that only one local application is needed to obtain lifelong clinical effect \[12\].
To date it is still debated how much the inflammation per se contributes to pain in osteoarthritis. A variety of studies have investigates various aspects such as synovitis but still no clear associations to pain have been found\[30\]. Many studies have attempted to modulate the effect of the inflammatory mediators on the pain receptors by e.g. interacting with the arachidonic acid pathways\[4\]. As such compounds have both peripheral and central effects it is difficult to use such compounds a specific modulators of specific local inflammatory processes. No compounds have so far been used to modulate selectively the local organelles specifically involved in the inflammatory processes of joint pain.
Gold particles seems as the only known method to obtain such a local effect on one specific element involved in the inflammatory process - the macrophages and the mast cells.
If a foreign object gets embedded in the body, macrophages will attack the object and digest it.
If the foreign object has a diameter bigger than 20 microns the macrophage cannot engulf it. Instead the macrophages create a membrane on the surface of the foreign body and starts a chemical attack in order to dissolve it.
If the foreign body consist of gold the macrophages will cause release of gold ions from the foreign body.
Gold ions, taken up by the macrophages, causes them to malfunction\[10,11,23\]. As the macrophage is 'conductor' of the inflammatory process it causes a drastic restraint of the inflammation and finally bring it to a stop\[22,25\]. The released gold ions will be taken up by the macrophages themselves, but also diffuse out into the surrounding tissue where they are taken up by other cells as well e.g. mast cells and other connective tissue cells\[7,32\]. When the gold ions accumulate in the secretory granules of mast cells it blocks histamine release and thereby decrease the local oedema and additionally suppresses pain.
The amount of bio-released gold ions are related to the intensity of inflammation. Only few gold ions are released in immunological nonreactive tissue. This means that if a local inflammation that has been treated with gold implants, the increase in macrophages will cause an immediate inhibition of the inflammation.
The combined effect of gold ions on macrophages and mast cells is together believed to causes the significant reduction in pain following treatment with metallic gold particles. If this principle can be validated it may provide important information for development of new and better treatments for e.g. joint pain.
Recently, Seifert et al.\[34\] called for studies providing new insights into the mode of action of gold ions and suggest investigating the effects on key mechanisms involved in arthritis or other inflammatory conditions.
Recently, clinical studies have suggested the existence of a neuropathic component in OA pain \[5\]. Accumulating evidence has been indicating that painful OA patients show peripheral and central sensitization \[3,16\]. Quantitative sensory testing (QST) is a relevant way to assess peripheral and central sensitization in joint pain \[9\]. The majority of studies have administered mechanical stimuli, and the most commonly used modality have been pressure. A recent review concluded that that people with OA have lower Pressure Pain Thresholds (PPT), facilitated temporal summation and impaired conditioned (CPM) compared with healthy controls \[5\]. Also, recent evidence have link QST profiles to the development of chronic pain \[29,38\], which emphasises the importance of studying the central nervous system.
Inflammation markers have been correlated with the pain intensity \[35\], and systemic inflammation can leads to sensitization of peripheral nociceptors \[1\]. Recently it was reported that higher preoperative levels of TNF-α, MMP-13 and IL-6 in synovial fluid may indicate a smaller improvement in pain 2 years after TKR \[15\].
Injectable solutions of gold-thio-compounds have been used to treat rheumatoid arthritis for nearly 100 years \[13,21\]. Several studies suggest that gold ions reduces pain, joint swelling, inflammation, and increase joint motility \[24,31,33\]. Gold salt therapy (auranofin; RidauraR) has been vetted by the FDA and approved (May 1985) and recommended by the American College of Rheumatology as a Disease Modifying Anti Rheumatic Drug - DMARD (https://www.rheumatology.org).
Gold salts, whether injected or given orally, have been shown to be effective \[33,37\] in reducing joint pain. Studies report patients going to total remission \[28\] and others report a 30% reduction in symptoms \[20,27\]. In addition, Clark et al., 1997 \[8\] concluded in a Cochrane meta-analysis that systemic treatment with gold was highly effective compared to placebo.
The use of gold salt given systemically have been criticized, since when gold compounds are made to circulate systemically via the circulatory system after oral or parenteral administration, the gold ions reach essentially all tissues and organs. In some patients, organs that are not involved in the arthritic disease, such as the kidneys, liver, and skin are adversely affected by gold. About 30% of patients develop such remote-organ "side effects" and discontinue gold treatment \[20\]. In addition, newer drugs have been developed with efficacy almost equal to gold ions in many patients, and less toxic.
To overcome the toxicity, a method that captures the efficacy of the gold ions but eliminates the remote side effects have been developed\[10,23\]. Briefly, the method isolates the gold ions within the affected joints by injecting solid gold metal directly into the diseased joint, whereby a very slow dissolution and local diffusion deliver the therapeutic gold ions to affected areas within the joint. In this therapy, 99.99% pure gold implants are injected into the body.
Individual single beads are implanted with a 15-16 gauge needle based on an X-ray picture in deeply anesthetized animals close to the capsule of the affected joint(s) (videos www.goldtreat.com). Over 3000 dogs, and more than 100 horses have had this treatment for osteoarthritis at 50+ veterinary clinics and hospitals throughout Europe. (www.goldtreat.com ). Success rates of 50 - 70% are quoted (www.goldtreat.com), and a double-blind, placebo controlled study on dogs showed improvement in over 80% of the dogs, which continues for 18 months \[18\] as the gold particles remain in the joint\[26\].
The systemic concentration of released gold ions is low but clinically effective and because the gold ions do not spread in the organism, but instead stay local, the technique is safe \[12\]. The trials to date indicate that only one local application is needed to obtain lifelong clinical effect \[12\].
To date it is still debated how much the inflammation per se contributes to pain in osteoarthritis. A variety of studies have investigates various aspects such as synovitis but still no clear associations to pain have been found\[30\]. Many studies have attempted to modulate the effect of the inflammatory mediators on the pain receptors by e.g. interacting with the arachidonic acid pathways\[4\]. As such compounds have both peripheral and central effects it is difficult to use such compounds a specific modulators of specific local inflammatory processes. No compounds have so far been used to modulate selectively the local organelles specifically involved in the inflammatory processes of joint pain.
Gold particles seems as the only known method to obtain such a local effect on one specific element involved in the inflammatory process - the macrophages and the mast cells.
If a foreign object gets embedded in the body, macrophages will attack the object and digest it.
If the foreign object has a diameter bigger than 20 microns the macrophage cannot engulf it. Instead the macrophages create a membrane on the surface of the foreign body and starts a chemical attack in order to dissolve it.
If the foreign body consist of gold the macrophages will cause release of gold ions from the foreign body.
Gold ions, taken up by the macrophages, causes them to malfunction\[10,11,23\]. As the macrophage is 'conductor' of the inflammatory process it causes a drastic restraint of the inflammation and finally bring it to a stop\[22,25\]. The released gold ions will be taken up by the macrophages themselves, but also diffuse out into the surrounding tissue where they are taken up by other cells as well e.g. mast cells and other connective tissue cells\[7,32\]. When the gold ions accumulate in the secretory granules of mast cells it blocks histamine release and thereby decrease the local oedema and additionally suppresses pain.
The amount of bio-released gold ions are related to the intensity of inflammation. Only few gold ions are released in immunological nonreactive tissue. This means that if a local inflammation that has been treated with gold implants, the increase in macrophages will cause an immediate inhibition of the inflammation.
The combined effect of gold ions on macrophages and mast cells is together believed to causes the significant reduction in pain following treatment with metallic gold particles. If this principle can be validated it may provide important information for development of new and better treatments for e.g. joint pain.
Recently, Seifert et al.\[34\] called for studies providing new insights into the mode of action of gold ions and suggest investigating the effects on key mechanisms involved in arthritis or other inflammatory conditions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Inflammation
Osteo Arthritis Knee
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Pilot study
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gold
Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants).
Group Type
EXPERIMENTAL
Gold
Intervention Type
OTHER
Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gold
Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Knee OA diagnosed based on the American College of Rheumatology criteria, KL (Kellgren-Lawrence) X-ray grade ≧ 2, pain for \> 3months, maximal pain intensity VAS (visual analogue scale) ≧ 5 (0-10 scale) for the most painful knee during the last week. Knee joint effusion that can be aspirated
Exclusion Criteria
* Pregnancy
* Drug addiction defined as the use of cannabis, opioids or other drugs
* Previous neurologic, musculoskeletal or mental illnesses
* Lack of ability to cooperate
* Current use of medications that may affect the trial e.g. analgesics, anti-inflammatory drugs
* Recent history of acute pain affecting the lower limb and/or trunk
* Past history of a chronic pain condition
* Participation in other pain trials throughout the study period
* Drug addiction defined as the use of cannabis, opioids or other drugs
* Previous neurologic, musculoskeletal or mental illnesses
* Lack of ability to cooperate
* Current use of medications that may affect the trial e.g. analgesics, anti-inflammatory drugs
* Recent history of acute pain affecting the lower limb and/or trunk
* Past history of a chronic pain condition
* Participation in other pain trials throughout the study period
Minimum Eligible Age
40 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aalborg University
OTHER
Sponsor Role
collaborator
Sten Rasmussen, MD, PhD
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sten Rasmussen, MD, PhD
Professor Head of Department of Clinical Medicine
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lars Arendt-Nielsen, MD, PhD
Role: STUDY_CHAIR
Aalborg University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aalborg University Hospital
Aalborg, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003 Dec;106(3):337-345. doi: 10.1016/j.pain.2003.08.001.
Reference Type
BACKGROUND
Andrew D, Greenspan JD. Mechanical and heat sensitization of cutaneous nociceptors after peripheral inflammation in the rat. J Neurophysiol. 1999 Nov;82(5):2649-56. doi: 10.1152/jn.1999.82.5.2649.
Reference Type
RESULT
Arendt-Nielsen L, Egsgaard LL, Petersen KK, Eskehave TN, Graven-Nielsen T, Hoeck HC, Simonsen O. A mechanism-based pain sensitivity index to characterize knee osteoarthritis patients with different disease stages and pain levels. Eur J Pain. 2015 Nov;19(10):1406-17. doi: 10.1002/ejp.651. Epub 2014 Dec 29.
Reference Type
RESULT
Arendt-Nielsen L, Nie H, Laursen MB, Laursen BS, Madeleine P, Simonsen OH, Graven-Nielsen T. Sensitization in patients with painful knee osteoarthritis. Pain. 2010 Jun;149(3):573-581. doi: 10.1016/j.pain.2010.04.003. Epub 2010 Apr 24.
Reference Type
RESULT
Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-1644. doi: 10.1097/j.pain.0000000000000562.
Reference Type
RESULT
Arendt-Nielsen L, Skou ST, Nielsen TA, Petersen KK. Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain. Curr Osteoporos Rep. 2015 Aug;13(4):225-34. doi: 10.1007/s11914-015-0276-x.
Reference Type
RESULT
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988 Dec;15(12):1833-40.
Reference Type
RESULT
Christensen MM, Danscher G, Ellermann-Eriksen S, Schionning JD, Rungby J. Autometallographic silver-enhancement of colloidal gold particles used to label phagocytic cells. Histochemistry. 1992;97(3):207-11. doi: 10.1007/BF00267629.
Reference Type
RESULT
Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, Suarez-Almazor ME. Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;1997(2):CD000520. doi: 10.1002/14651858.CD000520.
Reference Type
RESULT
Courtney CA, Kavchak AE, Lowry CD, O'Hearn MA. Interpreting joint pain: quantitative sensory testing in musculoskeletal management. J Orthop Sports Phys Ther. 2010 Dec;40(12):818-25. doi: 10.2519/jospt.2010.3314. Epub 2010 Oct 22.
Reference Type
RESULT
Danscher G. In vivo liberation of gold ions from gold implants. Autometallographic tracing of gold in cells adjacent to metallic gold. Histochem Cell Biol. 2002 May;117(5):447-52. doi: 10.1007/s00418-002-0400-8. Epub 2002 Apr 13.
Reference Type
RESULT
Danscher G, Stoltenberg M. Silver enhancement of quantum dots resulting from (1) metabolism of toxic metals in animals and humans, (2) in vivo, in vitro and immersion created zinc-sulphur/zinc-selenium nanocrystals, (3) metal ions liberated from metal implants and particles. Prog Histochem Cytochem. 2006;41(2):57-139. doi: 10.1016/j.proghi.2006.06.001. Epub 2006 Aug 7.
Reference Type
RESULT
Forestier J. Rheumatoid arthritis and its treatment by gold salts. The lancet 1934;224:646-648.
Reference Type
RESULT
Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006 Oct;22(10):1911-20. doi: 10.1185/030079906X132488.
Reference Type
RESULT
Gandhi R, Santone D, Takahashi M, Dessouki O, Mahomed NN. Inflammatory predictors of ongoing pain 2 years following knee replacement surgery. Knee. 2013 Oct;20(5):316-8. doi: 10.1016/j.knee.2012.10.015. Epub 2012 Nov 14.
Reference Type
RESULT
Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum. 2012 Sep;64(9):2907-16. doi: 10.1002/art.34466.
Reference Type
RESULT
Guy W, Bonato RR. Manual for the ECDEU assessment battery. : US Department of Health, Education, and Welfare, National Institute of Mental Health, 1970
Reference Type
RESULT
Jaeger GT, Larsen S, Soli N, Moe L. Two years follow-up study of the pain-relieving effect of gold bead implantation in dogs with hip-joint arthritis. Acta Vet Scand. 2007 Mar 23;49(1):9. doi: 10.1186/1751-0147-49-9.
Reference Type
RESULT
Jinks C, Jordan K, Croft P. Osteoarthritis as a public health problem: the impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology (Oxford). 2007 May;46(5):877-81. doi: 10.1093/rheumatology/kem013. Epub 2007 Feb 17.
Reference Type
RESULT
Jones G, Brooks PM. Injectable gold compounds: an overview. Br J Rheumatol. 1996 Nov;35(11):1154-8. doi: 10.1093/rheumatology/35.11.1154.
Reference Type
RESULT
Kean TA. Rheumatoid Arthritis and Gold Salts Therapy. Ulster Med J. 1934 Oct;3(4):284-9. No abstract available.
Reference Type
RESULT
Labens R, Lascelles BD, Charlton AN, Ferrero NR, Van Wettere AJ, Xia XR, Blikslager AT. Ex vivo effect of gold nanoparticles on porcine synovial membrane. Tissue Barriers. 2013 Apr 1;1(2):e24314. doi: 10.4161/tisb.24314.
Reference Type
RESULT
Larsen A, Kolind K, Pedersen DS, Doering P, Pedersen MO, Danscher G, Penkowa M, Stoltenberg M. Gold ions bio-released from metallic gold particles reduce inflammation and apoptosis and increase the regenerative responses in focal brain injury. Histochem Cell Biol. 2008 Oct;130(4):681-92. doi: 10.1007/s00418-008-0448-1. Epub 2008 Jun 10.
Reference Type
RESULT
Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J; METGO Study Group. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 2005 May;52(5):1360-70. doi: 10.1002/art.21018.
Reference Type
RESULT
Leonaviciene L, Kirdaite G, Bradunaite R, Vaitkiene D, Vasiliauskas A, Zabulyte D, Ramanaviciene A, Ramanavicius A, Asmenavicius T, Mackiewicz Z. Effect of gold nanoparticles in the treatment of established collagen arthritis in rats. Medicina (Kaunas). 2012;48(2):91-101. Epub 2012 Apr 5.
Reference Type
RESULT
Lie KI, Jaeger G, Nordstoga K, Moe L. Inflammatory response to therapeutic gold bead implantation in canine hip joint osteoarthritis. Vet Pathol. 2011 Nov;48(6):1118-24. doi: 10.1177/0300985810381910. Epub 2010 Sep 22.
Reference Type
RESULT
Meier FM, Frerix M, Hermann W, Muller-Ladner U. Current immunotherapy in rheumatoid arthritis. Immunotherapy. 2013 Sep;5(9):955-74. doi: 10.2217/imt.13.94.
Reference Type
RESULT
Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol. 1998 Oct;37(10):1060-8. doi: 10.1093/rheumatology/37.10.1060.
Reference Type
RESULT
Petersen KK, Arendt-Nielsen L, Simonsen O, Wilder-Smith O, Laursen MB. Presurgical assessment of temporal summation of pain predicts the development of chronic postoperative pain 12 months after total knee replacement. Pain. 2015 Jan;156(1):55-61. doi: 10.1016/j.pain.0000000000000022.
Reference Type
RESULT
Petersen KK, Siebuhr AS, Graven-Nielsen T, Simonsen O, Boesen M, Gudbergsen H, Karsdal M, Bay-Jensen AC, Arendt-Nielsen L. Sensitization and Serological Biomarkers in Knee Osteoarthritis Patients With Different Degrees of Synovitis. Clin J Pain. 2016 Oct;32(10):841-8. doi: 10.1097/AJP.0000000000000334.
Reference Type
RESULT
Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford). 2002 Feb;41(2):196-204. doi: 10.1093/rheumatology/41.2.196.
Reference Type
RESULT
Sadauskas E, Jacobsen NR, Danscher G, Stoltenberg M, Vogel U, Larsen A, Kreyling W, Wallin H. Biodistribution of gold nanoparticles in mouse lung following intratracheal instillation. Chem Cent J. 2009 Nov 20;3:16. doi: 10.1186/1752-153X-3-16.
Reference Type
RESULT
Sanders M. A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheumatol. 2000 Feb;27(2):523-9.
Reference Type
RESULT
Seifert O, Matussek A, Sjogren F, Geffers R, Anderson CD. Gene expression profiling of macrophages: implications for an immunosuppressive effect of dissolucytotic gold ions. J Inflamm (Lond). 2012 Nov 9;9(1):43. doi: 10.1186/1476-9255-9-43.
Reference Type
RESULT
Sturmer T, Brenner H, Koenig W, Gunther KP. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis. 2004 Feb;63(2):200-5. doi: 10.1136/ard.2003.007674.
Reference Type
RESULT
Williams HJ. Comparisons of sulfasalazine to gold and placebo in the treatment of rheumatoid arthritis. J Rheumatol Suppl. 1988 Sep;16:9-13.
Reference Type
RESULT
Wylde V, Sayers A, Lenguerrand E, Gooberman-Hill R, Pyke M, Beswick AD, Dieppe P, Blom AW. Preoperative widespread pain sensitization and chronic pain after hip and knee replacement: a cohort analysis. Pain. 2015 Jan;156(1):47-54. doi: 10.1016/j.pain.0000000000000002.
Reference Type
RESULT
Rasmussen S, Petersen KK, Aboo C, Andersen JS, Skjoldemose E, Jorgensen NK, Stensballe A, Arendt-Nielsen L. Intra-articular injection of gold micro-particles with hyaluronic acid for painful knee osteoarthritis. BMC Musculoskelet Disord. 2024 Mar 12;25(1):211. doi: 10.1186/s12891-024-07321-4.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-20160045
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Gold Factor on Knee Joint Health and Function
NCT05347602
COMPLETED
NA
The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis
NCT01383954
COMPLETED
PHASE4
Treatment of Osteoarthritis With Autologous, Microfragmented Adipose Tissue.
NCT03771989
UNKNOWN
NA
Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee
NCT01768975
COMPLETED
PHASE2
An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee
NCT00211549
COMPLETED
PHASE2
Efficacy Management and Adherence Evaluation of Diclofenac in the Treatment of Knee Osteoarthritis Pain
NCT03806205
UNKNOWN
NA
Effect of Anti-inflammatory Diet in Osteoarthritis
NCT06080347
RECRUITING
NA
Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.
NCT03379168
COMPLETED
NA
A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain
NCT04224584
COMPLETED
PHASE2
Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis
NCT05430230
ACTIVE_NOT_RECRUITING
PHASE4
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis
NCT01343303
COMPLETED
PHASE1
Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
NCT02104050
COMPLETED
PHASE2
Reinforcement of Placebo Response in Knee Osteoarthritis: A Randomised Trial
NCT05225480
COMPLETED
NA
Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee
NCT00542555
COMPLETED
PHASE3
Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis
NCT04238598
COMPLETED
NA
The Effect of Semiconductor Knee Sleeves on Pain in Osteoarthritis of the Knee.
NCT05255835
RECRUITING
NA
Clinical Trial on the Articular Pain of Diagnosed Patients of Arthrosis
NCT03525249
COMPLETED
NA
Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy
NCT01997138
WITHDRAWN
PHASE4
The Effect and Safety of Anti-inflammatories and Dextrose Prolotherapy Injections in Treating Knee Osteoarthritis
NCT06911359
RECRUITING
PHASE2
Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee
NCT00108810
COMPLETED
PHASE2
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
NCT04504812
COMPLETED
PHASE3
Understanding Pain Mechanisms in Knee Osteoarthritis
NCT05561010
UNKNOWN
NA
Effect of Glucosamine or Ibuprofen Combined With Physical Training in Patients With Knee-Osteoarthritis
NCT00833157
UNKNOWN
PHASE1
The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis
NCT03467919
COMPLETED
PHASE3
A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee
NCT00265304
COMPLETED
PHASE2